Trial Profile
Randomized Phase II Trial of Chemotherapy of Physician's Choice Plus Trastuzumab Versus Chemotherapy of Physician's Choice Plus Trastuzumab Plus Pertuzumab In Women With Pretreated, HER2-Overexpressing Metastatic Breast Cancer (MBC)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Dec 2022
Price :
$35
*
At a glance
- Drugs Pertuzumab (Primary) ; Capecitabine; Docetaxel; Paclitaxel; Trastuzumab; Vinorelbine
- Indications Advanced breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- Sponsors US Oncology Research
- 29 Nov 2022 Status changed from active, no longer recruiting to discontinued.
- 03 Dec 2021 Planned End Date changed from 31 Dec 2020 to 1 Jun 2022.
- 03 Dec 2021 Planned primary completion date changed from 31 Dec 2019 to 1 Jun 2022.